Chronic inflammatory demyelinating polyneuropathy after commencement of dupilumab for atopic dermatitis: Coincidence or contributory?

Ann Allergy Asthma Immunol. 2022 Jan;128(1):105-106. doi: 10.1016/j.anai.2021.08.415. Epub 2021 Sep 1.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Dermatitis, Atopic* / drug therapy
  • Humans
  • Male
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating* / chemically induced
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • dupilumab